Soleno Therapeutics, Inc. Common Stock (SLNO) Financials
Key financial figures for Soleno Therapeutics, Inc. Common Stock (Q1 2026).
- Revenue
- $95M
- Net Income
- $31M
- EPS
- $0.60
- Total Assets
- $608M
- Operating Cash Flow
- $26M
Full income statement, balance sheet, and cash flow for Soleno Therapeutics, Inc. Common Stock on SentiSense.